The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2007Target Identification of the Mitochondrial Parkinson's Disease PTEN-Induced Kinase 1
Mutations in PINK1 can cause Parkinson’s disease in certain familial PD cases. The exact cellular function of PINK1 and the impact of disease-relevant mutations remain unknown. PINK1 is known to...
-
Rapid Response Innovation Awards, 2007Development of SHG to Discover Drugs to Selectively Block AlphaS toxicity
Abnormal aggregation of normal or genetically mutated alpha-synuclein protein has been proposed as one possible mechanism for PD. Drugs that can target this abnormal change in the structure of the...
-
Target Validation, 2007Validation of Targets of Small Molecules that Ameliorate Alpha-synuclein Neurotoxicity
Objective/Rationale:
Using high-throughput screening, we have identified a small-molecule compound that rescues toxicity in a yeast model of Parkinson’s Disease and in mammalian neurons. This compound... -
Target Validation, 2007PGC-1 Alpha as a Neuroprotective Target in Parkinson’s Disease
Objective/Rationale:
Many treatments exist that can help to treat the symptoms of Parkinson's disease. But despite these "Symptoms & Side Effects" treatments, the disease continues to progress, with... -
Target Validation, 2007Validation of VPS41, a protein involved in lysosomal trafficking, as a target for Parkinson disease therapy
Objective/Rationale:
Two years ago, in an MJFF-funded search for proteins that are neuroprotective in a simple worm model of PD, the most promising target to emerge was VPS41, believed to be involved... -
Target Validation, 2007Validation of Cathepsin D as a target for Parkinson’s disease therapy
Objective/Rationale:
Cathepsin D is a lysosomal protease important for clearance of long-lived proteins. Alpha-synuclein aggregation is a cardinal pathologic feature of PD. Alpha-synuclein gene...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.